Phase 2 N=282 Mucin Balls and Corneal Inflammation Events
Corneal Inflammation · Corneal Infiltrative Events
Primary: Corneal Infiltrate Events - Phase I — 18.6; 5.7 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 4 N=50 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Allergic Conjunctivitis
Primary: Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1 — 3.12; 3.02 units on a scale
Phase 4 N=20 Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
Keratoconus, Unstable · Collagen Crosslinking · Postoperative Pain
Primary: Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3…
Phase 4 N=500 Steroids for Corneal Ulcers Trial
Corneal Ulcer · Eye Infections, Bacterial
Primary: Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 3 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate — 0.48; 0.49 logMAR — p=0.82
Phase 3 N=147 Cross-linking for Corneal Ulcers Treatment Trial
Corneal Ulcer · Infectious Keratitis · Bacterial Ulcer
Primary: Microbiological Cure on Repeat Culture — 5; 5; 17; 14 Participants
Phase 4 N=37 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
Dry Eye Disease
Primary: IVCM for Density of Corneal Immune Dendritiform Cells — 9.47; 28.60 cells/mm^2
Phase 4 N=16 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
Chronic Allergic Conjunctivitis
Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale
N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 4 N=94 Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface
Myopia · Refractive Error
Primary: Corneal Epithelial Immune Dendritic Cell Density (Central Cornea) — 46.2; 44.8; 62.3 cells/mm2
N/A N=24 Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear
Corneal Swelling
Primary: Percentage Change From Baseline of Corneal Swelling 8 Hours Post Fit — 0.07; -0.02; 0.14; -0.06 percentage of change from baseline
Phase 4 N=11 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale
Phase 2 N=130 Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Corneal Epithelial Disorders
Primary: Number of Participants With Clearing of Corneal Fluorescein Staining at Week 5 at Week 5 — 5; 7; 12 Participants
Phase 4 N=50 Corneal and Conjunctival Sensitivity and Staining Study
Myopia · Hyperopia
Primary: Corneal Sensitivity — 26.9; 25.5 percent CO2
Phase 4 N=131 Loteprednol vs. Prednisolone and Fluorometholone
Intraocular Pressure · Corneal Opacity
Primary: Change in Intraocular Pressure (IOP) From Baseline Through Month 3 — 14.38; 14.30; 13.67; 13.28 mmHg
Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105
Phase 4 N=167 Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Fuchs' Dystrophy · Corneal Edema
Primary: Intraocular Pressure — 11; 27 eyes
Phase 4 N=218 Daily Wear Corneal Infiltrative Event Study
Myopia · Hyperopia · Corneal Infiltrative Events
Primary: Number of Participants Developing a Corneal Inflammatory Event (CIE) — 6; 7 participants
N/A N=10 Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Sjogren's Disease
Primary: Ocular Surface Temperature of Both Eyes — 33.95; 34.3; 33.93; 33.95 degrees celcius
Phase 3 N=380 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
Ocular Infections, Irritations and Inflammations
Primary: Resolution of Anterior Chamber Cells — 48; 39; 19 Participants — p=.0024
N/A N=21 Effect of Olopatadine on Allergic Tear Mediators
Allergic Conjunctivitis
Primary: Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine…
Phase 4 N=50 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)
Post Operative Anterior Chamber Inflammation (Flare)
Primary: Anterior Chamber Inflammation (Flare) — 24.48; 21.93 photon count per msec (pc/ms)
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 3 N=178 Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
Cataract
Primary: Visual Ability (VA) — 0.91; 0.87 units on a scale (LogMAR) — p=0.065
Phase 2 N=102 Exploratory Study of OPC-12759 Ophthalmic Suspension
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
N/A N=35 Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Phase 3 N=147 Corneal Collagen Cross-linking for Progressive Keratoconus
Progressive Keratoconus
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -1.7; 0.6 diopters